DPYD polymorphisms c.496A>G , c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine‐based protocols-Reference-Cited by-同舟云学术

DPYD polymorphisms c.496A>G , c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine‐based protocols

Published:2021-12-06 Issue: Volume: Page:
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Božina Nada¹²,Bilić Ivan³⁴,Ganoci Lana²^ORCID,Šimičević Livija²,Pleština Stjepko³⁴,Lešnjaković Lucija⁵,Trkulja Vladimir¹

Affiliation:

1. Department of Pharmacology, School of Medicine University of Zagreb Zagreb Croatia

2. Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics University Hospital Centre Zagreb Zagreb Croatia

3. Department of Oncology University Hospital Centre Zagreb Zagreb Croatia

4. School of Medicine, University of Zagreb Croatia

5. Faculty of Pharmacy and Biochemistry University of Zagreb Zagreb Croatia

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15144

Reference56 articles.

1. 5‐Fluorouracil: mechanisms of action and clinical strategies;Longley DB;Nat Rev Cancer,2003

2. Genetic markers of toxicity from capecitabine and other fluorouracil‐based regimens: investigation in the QUASAR2 study, systematic review, and meta‐analysis;Rosmarin D;J Clin Oncol,2014

3. Capecitabine as adjuvant treatment for stage III colon cancer;Twelves C;N Engl J Med,2005

4. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first‐line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study;Hoff PM;J Clin Oncol,2001

5. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5‐fluorouracil;Kuilenburg ABP;Eur J Cancer,2004

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dihydropyrimidine Dehydrogenase Polymorphism c.2194G>A Screening Is a Useful Tool for Decreasing Gastrointestinal and Hematological Adverse Drug Reaction Risk in Fluoropyrimidine-Treated Patients;Current Issues in Molecular Biology;2024-09-04

2. MIR27A Gene Polymorphism Modifies the Effect of Common DPYD Gene Variants on Severe Toxicity in Patients with Gastrointestinal Tumors Treated with Fluoropyrimidine-Based Anticancer Therapy;International Journal of Molecular Sciences;2024-08-04

3. Fluoropyrimidine Toxicities and DPYD Genotyping: A Clinical Case;Cureus;2024-07-04

4. Pharmacogenetic markers of toxicity of FOLFOX/XELOX chemotherapy in patients with gastrointestinal tumors: a prospective observational study;Meditsinskiy sovet = Medical Council;2023-11-02

5. Liquid biopsy: an innovative and reliable method for detecting not only somatic, but also germline mutations in patients with colorectal and non-small cell lung carcinoma;Biotechnology & Biotechnological Equipment;2023-08-26